Immix Biopharma
- Market cap
- 788.42M
- P/E (TTM)i
- -10.78
- P/Bi
- 3.44
- EPSi
- -0.89
- Div yieldi
- 0.00%
- 52W posi
- 56%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 12.0 percentage points.
Institutional ownership
- Held by institutions
- 74.77% -11.95pp
- Institutions
- 136 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 47 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Yekaterina Chudnovsky | Director | 3.91% |
| Ilya Rachman | Chairperson & CEO | 1.38% |
| Jason Hsu | Director | 1.14% |
| Patricia Gallup | -- | 0.60% |
| Nancy Chang | Director | 0.51% |
| Gabriel Morris | Chief Financial Officer | 0.35% |
| Helen Adams | Independent Director | 0.21% |
| Magda Marquet | Independent Director | 0.06% |
| Jane Buchan | Independent Director | 0.03% |
| Carey Ng | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-21 | Nancy Chang | Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Nancy Chang | Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Jane Buchan | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Jane Buchan | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Jason Hsu | Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Jason Hsu | Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Magda Marquet | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Magda Marquet | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Helen Adams | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Helen Adams | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Carey Ng | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Carey Ng | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Ilya Rachman | Chairperson & CEO | Other Derivative Acquisition | +500,000 | $8.78 |
| 2026-05-21 | Gabriel Morris | Chief Financial Officer | Other Derivative Acquisition | +500,000 | $8.78 |
| 2026-05-21 | Yekaterina Chudnovsky | Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Yekaterina Chudnovsky | Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2025-12-09 | Ilya Rachman | Chairperson & CEO | Open Market Acquisition | +746 | $6.67 |
| 2025-12-09 | Gabriel Morris | Chief Financial Officer | Open Market Acquisition | +770 | $6.58 |
| 2025-12-07 | Alwaysraise LLC | -- | Derivative Exercise and Retained | +156,000 | $0.80 |
| 2025-11-20 | Nancy Chang | Director | Other Derivative Acquisition | +39,643 | $4.33 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:01:25 · For reference only, not investment advice and not tailored to your situation.